REG - Acacia Research Corp Arix Bioscience Plc - Statement Regarding Arix Bioscience plc

Arix BioscienceAnnouncement

04/05/2022 18:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220504:nRSD3688Ka&default-theme=true

RNS Number : 3688K  Acacia Research Corporation  04 May 2022

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR
FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

 

THIS ANNOUNCEMENT IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE
ON TAKEOVERS AND MERGERS (THE "CODE").

 

 

FOR IMMEDIATE RELEASE

 

 

4 May 2022

 

Acacia Research Corporation ("Acacia")

 

Statement regarding Arix Bioscience plc ("Arix" or "the Company")

 

Acacia―the permanent capital platform with investments in the life sciences
sector―announces that it has notified Arix of an acquisition of a further
646,832 shares in the Company, increasing its ownership to 27,182,317 shares,
which represents approximately 21.0% of Arix's issued share capital.

 

Acacia has notified the Board of Arix that it does not intend to make an Offer
for Arix and will be bound by that statement for the purposes of Rule 2.8 of
the UK's Takeover Code.

 

Clifford Press, Chief Executive Officer & President of Acacia, stated:

 

"We are pleased to take this opportunity to increase our shareholding in Arix.
In the last year, Arix has undertaken a number of steps to improve its
performance and corporate governance and we remain fully supportive of
management's strategy."

 

Rule 2.8 statement

 

Acacia confirms that it does not intend to make an offer for Arix. This is a
statement to which Rule 2.8 of the Takeover Code (the "Code") applies. Under
Note 2 on Rule 2.8 of the Code, Acacia reserves the right to set the
restrictions in Rule 2.8 aside in any of the following circumstances:

 

a)  with the agreement of the board of Arix;

 

b)  if a third party announces a firm intention to make an offer for Arix;

 

c)  if Arix announces a Rule 9 waiver proposal (see Note 1 of the Notes on
Dispensations from Rule 9) or a reverse takeover (as defined in the Code); or

 

d)  if there has been a material change of circumstances (as determined by
the Takeover Panel).

 

Contact details

 

Investor Contact:

FNK IR

Rob Fink, 646-809-4048

rob@fnkir.com

 

Media Contact:

Longacre Square Partners

Greg Marose, 646-386-0091

gmarose@longacresquare.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRAIMRTMTJMBMT